{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T11:07:34Z","timestamp":1782212854386,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31770837"],"award-info":[{"award-number":["31770837"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>MiRNAs are a group of multifunctional non-coding RNAs which play an important role in the various physiological processes including the development of NAFLD. Recent studies have shown that miR-30b-5p tightly associated with the abnormal lipid metabolism in patients with NAFLD, but the detailed mechanism of miR-30b-5p in the lipid metabolism was remain unclear. The aim of this study was to investigate the effect of miR-30b-5p on the lipid metabolism in hepatocellular carcinoma Huh-7 cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Material and methods<\/jats:title>\n                <jats:p>The correlation of intracellular fat content with the expression of miR-30b-5p in Huh-7 cells and HepG2 cells was investigated by treated cells with different concentrations of FFAs. The effect of miR-30b-5p on the lipid deposition in Huh-7 cells was tested by oil red O staining and TG concentrations measurement. qRT-PCR and western blot were used to investigate the lipid metabolism-related genes PPAR-\u03b1, SREBP-1, and GULT1 in miR-30b-5p overexpressed or inhibited Huh-7 cells. Target genes of miR-30b-5p were predicted using starBase, miRDB, and TargetScan databases and verified by qRT-PCR and western blot.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The expression of miR-30b-5p was significant decreased in the FFAs treated Huh-7 cells and HepG2 cells. Overexpressing miR-30b-5p in Huh-7 cells decreased the number and size of lipid droplets and intracellular TG concentrations in Huh-7 cells. Expression of fatty acid oxidation related gene PPAR-\u03b1 was increased and expression of lipid synthesis related gene SREBP-1 was decreased in the miR-30b-5p overexpressed Huh-7 cells. In addition, miR-30b-5p regulates the intracellular lipid metabolism by targeting PPARGC1A.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Overexpression of miR-30b-5p could reduce the intracellular fat deposition in Huh-7 cells, and miR-30b-5p might regulate the intracellular lipid metabolism by targeting the PPARGC1A in Huh-7 cells.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-020-01261-3","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T13:02:42Z","timestamp":1587042162000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["MiR-30b-5p regulates the lipid metabolism by targeting PPARGC1A in Huh-7 cell line"],"prefix":"10.1186","volume":"19","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-Feng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Zhen","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Kun","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shou-Sheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Ning","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"1261_CR1","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-8587(14)70032-4","volume":"2","author":"H Yki-Jarvinen","year":"2014","unstructured":"Yki-Jarvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. Lancet Diabetes Endocrinol. 2014;2:901\u201310.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1261_CR2","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1016\/j.jhep.2017.06.003","volume":"67","author":"JG Fan","year":"2017","unstructured":"Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67:862\u201373.","journal-title":"J Hepatol"},{"key":"1261_CR3","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1038\/ajg.2016.178","volume":"111","author":"Y Chang","year":"2016","unstructured":"Chang Y, Jung HS, Cho J, Zhang Y, Yun KE, Lazo M, Pastor-Barriuso R, Ahn J, Kim CW, Rampal S, et al. Metabolically healthy obesity and the development of nonalcoholic fatty liver disease. Am J Gastroenterol. 2016;111:1133\u201340.","journal-title":"Am J Gastroenterol"},{"key":"1261_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jhep.2016.08.019","volume":"66","author":"BK Koo","year":"2017","unstructured":"Koo BK, Kim D, Joo SK, Kim JH, Chang MS, Kim BG, Lee KL, Kim W. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol. 2017;66:123\u201331.","journal-title":"J Hepatol"},{"key":"1261_CR5","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jhep.2014.04.047","volume":"61","author":"VW Wong","year":"2014","unstructured":"Wong VW, Wong GL, Tse CH, Chan HL. Prevalence of the TM6SF2 variant and non-alcoholic fatty liver disease in Chinese. J Hepatol. 2014;61:708\u20139.","journal-title":"J Hepatol"},{"key":"1261_CR6","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.jhep.2008.11.021","volume":"50","author":"Y Li","year":"2009","unstructured":"Li Y, Xu C, Yu C, Xu L, Miao M. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009;50:1029\u201334.","journal-title":"J Hepatol"},{"key":"1261_CR7","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.1111\/dom.12973","volume":"19","author":"K Cusi","year":"2017","unstructured":"Cusi K, Sanyal AJ, Zhang S, Hartman ML, Bue-Valleskey JM, Hoogwerf BJ, Haupt A. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes. Diabetes Obes Metab. 2017;19:1630\u20134.","journal-title":"Diabetes Obes Metab"},{"key":"1261_CR8","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.05.013","volume":"65","author":"G Targher","year":"2016","unstructured":"Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016;65:589\u2013600.","journal-title":"J Hepatol"},{"key":"1261_CR9","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMra1503519","volume":"377","author":"AM Diehl","year":"2017","unstructured":"Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic Steatohepatitis. N Engl J Med. 2017;377:2063\u201372.","journal-title":"N Engl J Med"},{"key":"1261_CR10","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1261_CR11","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","volume":"65","author":"R Pais","year":"2016","unstructured":"Pais R, Barritt AS, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol. 2016;65:1245\u201357.","journal-title":"J Hepatol"},{"key":"1261_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"1261_CR13","doi-asserted-by":"crossref","unstructured":"Zhou F, Zhou J, Wang W, Zhang XJ, Ji YX, Zhang P, She ZG, Zhu L, Cai J, Li H: Unexpected Rapid Increase in the Burden of Nonalcoholic Fatty Liver Disease in China From 2008 to 2018: A systematic review and meta-analysis. Hepatology. 2019;70:1119-33.","DOI":"10.1002\/hep.30702"},{"key":"1261_CR14","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2019;156:1264\u201381 e1264.","journal-title":"Gastroenterology"},{"key":"1261_CR15","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/nature07228","volume":"455","author":"M Selbach","year":"2008","unstructured":"Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature. 2008;455:58\u201363.","journal-title":"Nature"},{"key":"1261_CR16","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.molcel.2004.07.007","volume":"15","author":"G Meister","year":"2004","unstructured":"Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004;15:185\u201397.","journal-title":"Mol Cell"},{"key":"1261_CR17","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nrm.2017.125","volume":"19","author":"G van Niel","year":"2018","unstructured":"van Niel G, D'Angelo G, Raposo G. Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol. 2018;19:213\u201328.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1261_CR18","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16:203\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"1261_CR19","doi-asserted-by":"publisher","first-page":"e302","DOI":"10.1111\/liv.12429","volume":"34","author":"H Miyaaki","year":"2014","unstructured":"Miyaaki H, Ichikawa T, Kamo Y, Taura N, Honda T, Shibata H, Milazzo M, Fornari F, Gramantieri L, Bolondi L, Nakao K. Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. Liver Int. 2014;34:e302\u20137.","journal-title":"Liver Int"},{"key":"1261_CR20","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jhep.2012.08.008","volume":"58","author":"RE Castro","year":"2013","unstructured":"Castro RE, Ferreira DM, Afonso MB, Borralho PM, Machado MV, Cortez-Pinto H, Rodrigues CM. miR-34a\/SIRT1\/p53 is suppressed by ursodeoxycholic acid in the rat liver and activated by disease severity in human non-alcoholic fatty liver disease. J Hepatol. 2013;58:119\u201325.","journal-title":"J Hepatol"},{"key":"1261_CR21","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1136\/gutjnl-2015-310044","volume":"65","author":"S Benhamouche-Trouillet","year":"2016","unstructured":"Benhamouche-Trouillet S, Postic C. Emerging role of miR-21 in non-alcoholic fatty liver disease. Gut. 2016;65:1781\u20133.","journal-title":"Gut"},{"key":"1261_CR22","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/gutjnl-2014-306996","volume":"64","author":"CJ Pirola","year":"2015","unstructured":"Pirola CJ, Fernandez Gianotti T, Castano GO, Mallardi P, San Martino J, Mar\u00eda MGLL, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut. 2015;64:800\u201312.","journal-title":"Gut"},{"key":"1261_CR23","doi-asserted-by":"publisher","first-page":"7466","DOI":"10.1038\/ncomms8466","volume":"6","author":"Y Xu","year":"2015","unstructured":"Xu Y, Zalzala M, Xu J, Li Y, Yin L, Zhang Y. A metabolic stress-inducible miR-34a-HNF4alpha pathway regulates lipid and lipoprotein metabolism. Nat Commun. 2015;6:7466.","journal-title":"Nat Commun"},{"key":"1261_CR24","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1136\/gutjnl-2014-308430","volume":"65","author":"H Wu","year":"2016","unstructured":"Wu H, Ng R, Chen X, Steer CJ, Song G. MicroRNA-21 is a potential link between non-alcoholic fatty liver disease and hepatocellular carcinoma via modulation of the HBP1-p53-Srebp1c pathway. Gut. 2016;65:1850\u201360.","journal-title":"Gut"},{"key":"1261_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.3892\/ijmm.2015.2076","volume":"35","author":"C Sun","year":"2015","unstructured":"Sun C, Huang F, Liu X, Xiao X, Yang M, Hu G, Liu H, Liao L. miR-21 regulates triglyceride and cholesterol metabolism in non-alcoholic fatty liver disease by targeting HMGCR. Int J Mol Med. 2015;35:847\u201353.","journal-title":"Int J Mol Med"},{"key":"1261_CR26","first-page":"9623412","volume":"2018","author":"L Mao","year":"2018","unstructured":"Mao L, Liu S, Hu L, Jia L, Wang H, Guo M, Chen C, Liu Y, Xu L. miR-30 family: a promising regulator in development and disease. Biomed Res Int. 2018;2018:9623412.","journal-title":"Biomed Res Int"},{"key":"1261_CR27","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1038\/ijo.2017.21","volume":"41","author":"J Latorre","year":"2017","unstructured":"Latorre J, Moreno-Navarrete JM, Mercader JM, Sabater M, Rovira O, Girones J, Ricart W, Fernandez-Real JM, Ortega FJ. Decreased lipid metabolism but increased FA biosynthesis are coupled with changes in liver microRNAs in obese subjects with NAFLD. Int J Obes. 2017;41:620\u201330.","journal-title":"Int J Obes"},{"key":"1261_CR28","doi-asserted-by":"crossref","unstructured":"Dai LL, Li SD, Ma YC, Tang JR, Lv JY, Zhang YQ, Miu YL, Ma YQ, Li CM, Chu YY, et al. MicroRNA-30b regulates insulin sensitivity by targeting SERCA2b in non-alcoholic fatty liver disease. Liver Int. 2019;39:1504-13.","DOI":"10.1111\/liv.14067"},{"key":"1261_CR29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cbi.2006.11.004","volume":"165","author":"MJ Gomez-Lechon","year":"2007","unstructured":"Gomez-Lechon MJ, Donato MT, Martinez-Romero A, Jimenez N, Castell JV, O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact. 2007;165:106\u201316.","journal-title":"Chem Biol Interact"},{"key":"1261_CR30","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/j.1440-1746.2008.05733.x","volume":"24","author":"M Ricchi","year":"2009","unstructured":"Ricchi M, Odoardi MR, Carulli L, Anzivino C, Ballestri S, Pinetti A, Fantoni LI, Marra F, Bertolotti M, Banni S, et al. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes. J Gastroenterol Hepatol. 2009;24:830\u201340.","journal-title":"J Gastroenterol Hepatol"},{"key":"1261_CR31","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1038\/s41467-018-05182-9","volume":"9","author":"F Ghini","year":"2018","unstructured":"Ghini F, Rubolino C, Climent M, Simeone I, Marzi MJ, Nicassio F. Endogenous transcripts control miRNA levels and activity in mammalian cells by target-directed miRNA degradation. Nat Commun. 2018;9:3119.","journal-title":"Nat Commun"},{"key":"1261_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.biomaterials.2017.05.032","volume":"139","author":"FF Adams","year":"2017","unstructured":"Adams FF, Heckl D, Hoffmann T, Talbot SR, Kloos A, Thol F, Heuser M, Zuber J, Schambach A, Schwarzer A. An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. Biomaterials. 2017;139:102\u201315.","journal-title":"Biomaterials"},{"key":"1261_CR33","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1261_CR34","doi-asserted-by":"publisher","first-page":"D146","DOI":"10.1093\/nar\/gku1104","volume":"43","author":"N Wong","year":"2015","unstructured":"Wong N. Wang X: miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43:D146\u201352.","journal-title":"Nucleic Acids Res"},{"key":"1261_CR35","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13059-019-1629-z","volume":"20","author":"W Liu","year":"2019","unstructured":"Liu W, Wang X. Prediction of functional microRNA targets by integrative modeling of microRNA binding and target expression data. Genome Biol. 2019;20:18.","journal-title":"Genome Biol"},{"key":"1261_CR36","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1038\/nrgastro.2013.87","volume":"10","author":"G Szabo","year":"2013","unstructured":"Szabo G, Bala S. MicroRNAs in liver disease. Nat Rev Gastroenterol Hepatol. 2013;10:542\u201352.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1261_CR37","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1136\/gutjnl-2018-318146","volume":"68","author":"M Gjorgjieva","year":"2019","unstructured":"Gjorgjieva M, Sobolewski C, Dolicka D. Correia de Sousa M, Foti M: miRNAs and NAFLD: from pathophysiology to therapy. Gut. 2019;68:2065\u201379.","journal-title":"Gut"},{"key":"1261_CR38","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.tem.2017.11.009","volume":"29","author":"X Palomer","year":"2018","unstructured":"Palomer X, Pizarro-Delgado J, Barroso E, Vazquez-Carrera M. Palmitic and oleic acid: the Yin and Yang of fatty acids in type 2 diabetes mellitus. Trends Endocrinol Metab. 2018;29:178\u201390.","journal-title":"Trends Endocrinol Metab"},{"key":"1261_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/hep.20283","volume":"40","author":"AE Feldstein","year":"2004","unstructured":"Feldstein AE, Werneburg NW, Canbay A, Guicciardi ME, Bronk SF, Rydzewski R, Burgart LJ, Gores GJ. Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway. Hepatology. 2004;40:185\u201394.","journal-title":"Hepatology"},{"key":"1261_CR40","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1136\/gutjnl-2017-313778","volume":"67","author":"M Li","year":"2018","unstructured":"Li M, Xu C, Shi J, Ding J, Wan X, Chen D, Gao J, Li C, Zhang J, Lin Y, et al. Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfurtransferase\/hydrogen sulfide pathway. Gut. 2018;67:2169\u201380.","journal-title":"Gut"},{"key":"1261_CR41","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.biopha.2017.02.062","volume":"89","author":"X Qin","year":"2017","unstructured":"Qin X, Chen J, Wu L, Liu Z. MiR-30b-5p acts as a tumor suppressor, repressing cell proliferation and cell cycle in human hepatocellular carcinoma. Biomed Pharmacother. 2017;89:742\u201350.","journal-title":"Biomed Pharmacother"},{"key":"1261_CR42","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jhep.2014.10.039","volume":"62","author":"M Pawlak","year":"2015","unstructured":"Pawlak M, Lefebvre P, Staels B. Molecular mechanism of PPARalpha action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease. J Hepatol. 2015;62:720\u201333.","journal-title":"J Hepatol"},{"key":"1261_CR43","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/nrendo.2017.91","volume":"13","author":"H Shimano","year":"2017","unstructured":"Shimano H, Sato R. SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology. Nat Rev Endocrinol. 2017;13:710\u201330.","journal-title":"Nat Rev Endocrinol"},{"key":"1261_CR44","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.molcel.2017.05.020","volume":"67","author":"S Roy","year":"2017","unstructured":"Roy S, Leidal AM, Ye J, Ronen SM, Debnath J. Autophagy-dependent shuttling of TBC1D5 controls plasma membrane translocation of GLUT1 and glucose uptake. Mol Cell. 2017;67:84\u201395 e85.","journal-title":"Mol Cell"},{"key":"1261_CR45","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1210\/er.2006-0037","volume":"27","author":"C Handschin","year":"2006","unstructured":"Handschin C, Spiegelman BM. Peroxisome proliferator-activated receptor gamma coactivator 1 coactivators, energy homeostasis, and metabolism. Endocr Rev. 2006;27:728\u201335.","journal-title":"Endocr Rev"},{"key":"1261_CR46","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/nm1044","volume":"10","author":"SH Koo","year":"2004","unstructured":"Koo SH, Satoh H, Herzig S, Lee CH, Hedrick S, Kulkarni R, Evans RM, Olefsky J, Montminy M. PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med. 2004;10:530\u20134.","journal-title":"Nat Med"},{"key":"1261_CR47","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.jhep.2014.06.032","volume":"61","author":"MJ Park","year":"2014","unstructured":"Park MJ, Kim DI, Lim SK, Choi JH, Kim JC, Yoon KC, Lee JB, Lee JH, Han HJ, Choi IP, et al. Thioredoxin-interacting protein mediates hepatic lipogenesis and inflammation via PRMT1 and PGC-1alpha regulation in vitro and in vivo. J Hepatol. 2014;61:1151\u20137.","journal-title":"J Hepatol"},{"key":"1261_CR48","doi-asserted-by":"publisher","first-page":"169","DOI":"10.7150\/ijms.13581","volume":"13","author":"H Maruyama","year":"2016","unstructured":"Maruyama H, Kiyono S, Kondo T, Sekimoto T, Yokosuka O. Palmitate-induced regulation of PPARgamma via PGC1alpha: a mechanism for lipid accumulation in the liver in nonalcoholic fatty liver disease. Int J Med Sci. 2016;13:169\u201378.","journal-title":"Int J Med Sci"},{"key":"1261_CR49","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41575-018-0089-3","volume":"16","author":"E Piccinin","year":"2019","unstructured":"Piccinin E, Villani G, Moschetta A. Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators. Nat Rev Gastroenterol Hepatol. 2019;16:160\u201374.","journal-title":"Nat Rev Gastroenterol Hepatol"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-020-01261-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-020-01261-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T01:22:15Z","timestamp":1618536135000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-020-01261-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1261"],"URL":"https:\/\/doi.org\/10.1186\/s12944-020-01261-3","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"31 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"76"}}